IVA (IVA) Stock Price & Analysis
IVA (IVA) fell 4.71% to USD 4.45 as of September 9, 2026 at 22:49 UTC, according to Nexqual real-time market data.
IVA last closed at USD 4.67; the session ranged USD 4.29–4.66 on volume of 1,975,012 shares. Market capitalization is $1.05B, with a 52-week range of USD 3.35–7.98 (NGM). Source: Nexqual, September 9, 2026 at 22:49 UTC.
Key Statistics (as of September 9, 2026 at 22:49 UTC)
| Price | USD 4.45 |
|---|---|
| Change | ▼ 4.71% (down) |
| Previous Close | USD 4.67 |
| Open | USD 4.66 |
| Day Range | USD 4.29 – 4.66 |
| 52-Week Range | USD 3.35 – 7.98 |
| Volume | 1,975,012 shares |
| Market Cap | $1.05B |
| Exchange | NGM |
Technical Analysis (IVA)
Nexqual's technical model rates IVA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of September 9, 2026 at 22:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.3 (neutral) |
| vs SMA50 | Below (USD 4.54) |
| MACD | 0.04 (positive) |
Analyst Ratings (IVA)
Wall Street analysts rate IVA "Strong Buy" based on 12 analysts, with a mean price target of USD 14.62 (range USD 8.8–26), per Nexqual as of September 9, 2026 at 22:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 14.62 |
| High Target | USD 26 |
| Low Target | USD 8.8 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (IVA)
| Next Earnings Date | 2026-09-28 |
|---|---|
| Revenue Estimate | $0 |
Source: Nexqual, September 9, 2026 at 22:49 UTC.
Financials & Fundamentals (IVA)
| Total Revenue | $6.76M |
|---|---|
| Revenue Growth (YoY) | -89.90% |
| Gross Margin | +99.68% |
| Operating Margin | -6710.69% |
| Profit Margin | +0.00% |
| Current Ratio | 3.16 |
| Total Cash | $99.84M |
| Total Debt | $230.89M |
| Free Cash Flow | $-200.71M |
Source: Nexqual, September 9, 2026 at 22:49 UTC.
Financial Health Score (IVA)
Nexqual rates IVA's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 22:49 UTC.
| Growth | Critical — Revenue -51% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $100M cash vs $231M debt |
| Cash Flow | Weak — FCF negative: -$201M, burning cash |
| Efficiency | Mixed — No data |
Ownership (IVA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +41.80% |
| Shares Outstanding | 236.22M |
| Float | 157.92M |
| Short % of Float | +1.16% |
Source: Nexqual, September 9, 2026 at 22:49 UTC.
Leadership (IVA)
IVA is led by Andrew Obenshain (age 51), Chief Executive Officer, per Nexqual as of September 9, 2026 at 22:49 UTC.
| Chief Executive Officer | Andrew Obenshain (age 51) |
|---|---|
| President of Research & Development and Chief Medical Officer | Jason A. Campagna (age 59) |
| Chief Financial Officer | Axel-Sven Malkomes (age 58) |
Major Backers & Investors (IVA)
Notable institutional backers of IVA include Caligan Partners, LP, Samsara BioCapital, LLC, Paradigm Biocapital Advisors LP, according to Nexqual as of September 9, 2026 at 22:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Caligan Partners, LP | 3.91% |
| Samsara BioCapital, LLC | 3.02% |
| Paradigm Biocapital Advisors LP | 1.91% |
| Andera Partners | 1.74% |
| Adar1 Capital Management, LLC | 1.73% |
| Millennium Management | 1.68% |
| Nantahala Capital Management, LLC | 1.29% |
| Trails Edge Capital Partners, LP | 1.27% |
Source: Nexqual, September 9, 2026 at 22:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANNX | Annexon, Inc. | USD 4.37 | ▼ 10.27% |
| IPHA | Innate Pharma S.A. | USD 1.95 | ▼ 6.25% |
| NBTX | Nanobiotix S.A. | USD 36.64 | ▼ 5.57% |
| INBX | Inhibrx Biosciences, Inc. | USD 112.86 | ▼ 6.86% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.67 | ▼ 5.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 22:49 UTC. This page is informational and not investment advice.